Market Cap | 3.37M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -17.09M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -11.00% |
Sales | - | PEG | - | EPS past 5Y | 26.11% | 200D Avg Chg | -34.00% |
Dividend | N/A | Price/Book | 0.25 | EPS next 5Y | - | 52W High Chg | -78.00% |
Recommedations | - | Quick Ratio | 0.05 | Shares Outstanding | 8.59M | 52W Low Chg | 8.00% |
Insider Own | 6.61% | ROA | -9.09% | Shares Float | 7.81M | Beta | 2.18 |
Inst Own | 5.32% | ROE | -122.02% | Shares Shorted/Prior | 250.53K/190.18K | Price | 0.93 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 58,108 | Target Price | - |
Oper. Margin | - | Earnings Date | May 22 | Volume | 14,111 | Change | -0.25% |
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. Its lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.